grammy winners obama budget news channel 5 stacy francis woolly mammoth belize resorts nikki minaj grammy performance
Saturday, February 18, 2012
Obama promotes steps to boost US trade (AP)
[unable to retrieve full-text content]
Friday, February 17, 2012
Beat Eczema ? 3 unbelievable Ways to Beat Eczema With absent ...
In this article I will show you how to treat and cure your eczema naturally and organically. This means no more expensive creams, lotions or pills for life!
Eczema affects millions worldwide, recent studies show that more than 34 million patients with dermatitis of the skin around the world. And those numbers are growing every year.
That?s why I decided to write this article, so I share 3 killer ways to treat and cure Beat Eczema with one hundred percent natural and organic methods.
I will show you that you do not need any type of medication (creams, lotions or pills) to treat skin rashes.
Creams, lotions and pills are effective in the treatment of eczema, but they are extremely expensive and, more importantly, they also cause dangerous side effects (like all other drugs chemically produced).
Organic and natural medicines, on the other hand, have zero side effects and give you amazing results! Why biomedicine has side effects is zero, because, unlike drugs, they are aggressive chemicals, bio-medicine is made from natural ingredients such as fruits, vegetables, plants and minerals.
Caustic chemicals can react badly to an allergic human body and can cause dangerous side effects. Fruits, vegetables, plants and minerals are made to be digested and the human body and therefore there is absolutely no risk of side effects.
So what are the three remedies natural killer and organic eczema? Here are your answers.
No. 1: Avoid direct contact of detergents, soaps, perfumes (perfume / aftershave) and includes any other products, aggressive chemicals. These products may slightly increase your Beat eczema quickly and spread throughout the body. Therefore, they avoid as much as you can then you suffer from this embarrassing skin condition.
No. 2 water: eczema, as you know, is a skin disease, drought, itching, irritation, redness and inflammation. People are used to buy medical creams to reduce dryness and irritation, but as you know, these creams are made from harsh chemicals. This is why I recommend instead of buying those expensive creams and dangerous medical, drinking 2/3 liters of water per day. Why? Because water is a natural body and skin moisturizer and the difference of medical creams, water provides no side effects! By simply drinking 2/3 liter of water per day, not only your body and skin with moisture, but also to prevent dehydration.
# 3 Cotton: Cotton is a very soft material, smooth and itchy. Wearing cotton clothing, you greatly reduce the annoying itch of eczema causes.
breaking dawn part 2 breaking dawn part 2 whitney cummings associated press msnbc i will always love you maine caucus
Bottom Line - Zynga shares tumble as user growth slows to a crawl
NBC
Social gaming company Zynga.
By msnbc.com news services
Updated at?4:58 p.m. ET:
Shares of Zynga tumbled 18 percent Wednesday after the?online gaming company reported that user growth slowed in the final three months of 2011, raising fears about how it will generate revenue growth in the future.
In its first-ever earnings report as a public company, the maker of the popular Farmville and Cityville games said Tuesday it had 54 million active daily users in the three months ended Dec. 31, up 13 percent from 48 million a year ago, but flat from the number of users in the previous quarter.
Zynga also said it lost $435 million, or $1.22 per share, in the fourth quarter on $311 million in revenue. The company, which?trades under the symbol ZNGA on the Nasdaq, fell?$2.55 to close at $11.80 a share.
?They have to work harder to get existing traffic to pay more. That?s a challenging proposition,? said Sterne Agee, an analyst Arvind Bhatia.
One of a crop of new social media technology companies that have launched on the public markets recently, Zynga went public at $10 a share last December, raising $1 billion. Its stock price closed Tuesday at an all-time high of $14.35, up 79 percent from a low of $8 hit on Jan. 9.
Investors are watching to see how the likes of LinkedIn, Pandora and Groupon do ahead of the expected stock market debut of Facebook -- an IPO that?s expected to be one of the most closely followed in recent memory.
Zynga is of particular interest when it comes to Facebook.
In its IPO prospectus last year the gaming site said that 94 percent of its revenue comes from Facebook. On Tuesday, it did not break out a figure for its Facebook revenue, which makes it harder for investors to fathom whether it is reducing its reliance on the social network.
?I think it would helpful for them to report a breakdown between mobile and social,? said Baird Research analyst Colin Sebastian.
Given Zynga's dependence on Facebook for the vast majority of its revenue, investors are closely watching its strategy to diversify and make money from games on smartphones and tablets. Zynga said on Tuesday that it ended the year with 15 million daily mobile users, a five-fold increase from a year earlier.
In its Securities and Exchange Commission filing for an IPO, Facebook revealed that about 12 percent of its revenue comes from Zynga.
Reuters contributed to this story.
tangled ever after last house on the left last house on the left rich forever mixtape blow i am legend the unit
Thursday, February 16, 2012
Popgadget Personal Technology for Women: Is the GoPad genius or ...
- RSS 2.0
- XML/Atom
- Add to Yahoo
- Bloglines
- Popgadget
- Babygadget
- CNET
- We-Make-Money-
Not-Art - Kitchen Contraptions
- Cooking Gadgets
- Textually
- SheFinds
- Pocketables
- Plastic Bamboo
- Engadget
- Cool Hunting
- Inhabitat
- misBehaving
- design*sponge
- Gizmodo
- ShinyShiny
- The Gadgeteer
- Wonderland
- Oh Gizmo!
- Tree Hugger
- Lifehacker
- Ubergizmo
- Book of Joe
- Eyebeam reBlog
- Medgadget
- Julia Set
- Game Girl Advance
- See Art / Make Art
- Cribcandy
- Tech_space
- Smart Stuff
- Mental Floss
- Social Bookmarking
02. 13. 2012
The GoPad device essentially straps your iPad to your chest, yes it looks a bit ridiculous, but we can imagine it being really useful for doctors or teachers. We think...
Available from GoPad.
[Via Like Cool]
Posted by Becca ???Category: devices
Tags:
Email this | Comments (0) 
Post a comment
(If you haven't left a comment here before, you may need to be approved by the site owner before your comment will appear. Until then, it won't appear on the entry. Thanks for waiting.)
Back to Top
?
| ? |  | |||||||||||||||||||||||
| ||||||||||||||||||||||||
| | ||||||||||||||||||||||||
Source: http://www.popgadget.net/2012/02/is_the_gopad_ge.php
yahoo.com/mail david nelson david nelson frank miller 60 minutes oobleck justin timberlake marine corps ball
'First-in-human' drug for malignant glioma available in experimental trial
![[ Back to EurekAlert! ]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_vMMvJJbv6o8P_yzSvarsJjNKbxuI5u6X1wxAqYwVjk3Ic1u2fE3IxoTL7r5BwfXBdMnOCzPgcJAO5EHRpwpZ2UFErneemIqwFaPK7oyvA=s0-d){kind=small}
Public release date: 15-Feb-2012[ | E-mail |
Share ] Contact: Amanda Harper
amanda.harper@uc.edu
513-558-4657
University of Cincinnati Academic Health Center
CINCINNATI -- The UC Cancer Institute is one of three centers internationally approved to test an experimental drug's safety and pharmacokinetics and also assess the clinical benefit against recurrent malignant glioma, an aggressive form of brain cancer.
The "first-in-human" phase-1 trial is expected to enroll up to 60 patients at clinical sites in the United States and Australia.
Led by Olivier Rixe, MD, PhD, this experimental drug trial uses antibody-drug conjugate (ADC) technology, a new drug delivery concept currently being investigated in the treatment of various cancers. ADC molecules consist of an antibody linked to a specific cytotoxic drug that is intended to target, bind and disperse only in malignant cells.
The experimental drug (called AMG 595) is intended to target a specific mutated cell receptor (EGFRvIII) which exists on the surface of tumor cells in up to 30 percent of patients with malignant gliomas. Preliminary studies in animals have shown that ADC molecules can effectively find these specific cancer cells, then enter them and release an active cytotoxic agent with the aim of killing the tumor cells while minimizing damage to the surrounding normal tissue.
"This allows us to use a highly cytotoxic drug targeted to the cancer cells in the brain based on a specific cellular marker," explains Rixe, John and Gladys Strauss Chair in Cancer Research at the UC College of Medicine and director of the Experimental Therapeutics/Phase 1 Clinical Trials Program. "Until recently, primary brain tumor patients have traditionally been excluded from phase-1 oncology studies, so finding drugs to effectively target and make real advances against this particular type of very aggressive cancer has been virtually impossible."
Patients who have failed first- and second-line therapies for malignant glioma may qualify to participate in this trial. Potential candidates will be screened for the EGFRvIII mutation using tumor samples obtained during their original surgery prior to enrollment.
Each patient's response to the treatment and overall health will be clinically monitored through blood, urine and imaging tests at regular intervals through the trial. Patients may be involved in the study for about eight months, including a pre-study assessment period and safety follow-up visit.
This is a paradigm shift in the way we look at gliomas, because the ADC model has the potential to revolutionize the way we deliver chemotherapy to cancer cells while sparing the surrounding healthy tissue." adds Rixe.
"Our goal is to improve the benefits-risk ratio of treatment by increasing anti-tumor activity while reducing the side effects of toxicity on healthy tissue."
The clinical trial of AMG 595, the experimental drug being used in the study, is sponsored by Amgen, a biotechnology company based in Thousand Oaks, California.
More than 22,000 people in the United States are diagnosed with a primary malignant brain tumor every year, according to the National Cancer Institute, and the majority of these are malignant gliomas which have a poor prognosis.
In 2011, the UC Cancer Institute partnered with the UC Neuroscience Institute's Brain Tumor Center to launch a translational research program aimed at understanding the biological mechanisms of cancer's spread to the brain and developing more effective ways to treat the condition.
Both programs are part of the Cincinnati Cancer Center, a joint cancer program involving the UC College of Medicine, Cincinnati Children's Hospital Medical Center and UC Health. The collaborative initiative brings together interdisciplinary research teams of caring scientists and health professionals to research and develop new cures, while providing a continuum of care for children, adults and families with cancer.
###
For more information about phase-1 studies at the UC Cancer Institute, call 513-584-7698 or 866-724-CURE-2873. To learn more about the Experimental Therapeutics Program, visit cancer.uc.edu. Rixe treats patients at the Barrett Center and University Hospital as part of UC Health's multidisciplinary neuro-oncology team.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 15-Feb-2012[ | E-mail |
Share ] Contact: Amanda Harper
amanda.harper@uc.edu
513-558-4657
University of Cincinnati Academic Health Center
CINCINNATI -- The UC Cancer Institute is one of three centers internationally approved to test an experimental drug's safety and pharmacokinetics and also assess the clinical benefit against recurrent malignant glioma, an aggressive form of brain cancer.
The "first-in-human" phase-1 trial is expected to enroll up to 60 patients at clinical sites in the United States and Australia.
Led by Olivier Rixe, MD, PhD, this experimental drug trial uses antibody-drug conjugate (ADC) technology, a new drug delivery concept currently being investigated in the treatment of various cancers. ADC molecules consist of an antibody linked to a specific cytotoxic drug that is intended to target, bind and disperse only in malignant cells.
The experimental drug (called AMG 595) is intended to target a specific mutated cell receptor (EGFRvIII) which exists on the surface of tumor cells in up to 30 percent of patients with malignant gliomas. Preliminary studies in animals have shown that ADC molecules can effectively find these specific cancer cells, then enter them and release an active cytotoxic agent with the aim of killing the tumor cells while minimizing damage to the surrounding normal tissue.
"This allows us to use a highly cytotoxic drug targeted to the cancer cells in the brain based on a specific cellular marker," explains Rixe, John and Gladys Strauss Chair in Cancer Research at the UC College of Medicine and director of the Experimental Therapeutics/Phase 1 Clinical Trials Program. "Until recently, primary brain tumor patients have traditionally been excluded from phase-1 oncology studies, so finding drugs to effectively target and make real advances against this particular type of very aggressive cancer has been virtually impossible."
Patients who have failed first- and second-line therapies for malignant glioma may qualify to participate in this trial. Potential candidates will be screened for the EGFRvIII mutation using tumor samples obtained during their original surgery prior to enrollment.
Each patient's response to the treatment and overall health will be clinically monitored through blood, urine and imaging tests at regular intervals through the trial. Patients may be involved in the study for about eight months, including a pre-study assessment period and safety follow-up visit.
This is a paradigm shift in the way we look at gliomas, because the ADC model has the potential to revolutionize the way we deliver chemotherapy to cancer cells while sparing the surrounding healthy tissue." adds Rixe.
"Our goal is to improve the benefits-risk ratio of treatment by increasing anti-tumor activity while reducing the side effects of toxicity on healthy tissue."
The clinical trial of AMG 595, the experimental drug being used in the study, is sponsored by Amgen, a biotechnology company based in Thousand Oaks, California.
More than 22,000 people in the United States are diagnosed with a primary malignant brain tumor every year, according to the National Cancer Institute, and the majority of these are malignant gliomas which have a poor prognosis.
In 2011, the UC Cancer Institute partnered with the UC Neuroscience Institute's Brain Tumor Center to launch a translational research program aimed at understanding the biological mechanisms of cancer's spread to the brain and developing more effective ways to treat the condition.
Both programs are part of the Cincinnati Cancer Center, a joint cancer program involving the UC College of Medicine, Cincinnati Children's Hospital Medical Center and UC Health. The collaborative initiative brings together interdisciplinary research teams of caring scientists and health professionals to research and develop new cures, while providing a continuum of care for children, adults and families with cancer.
###
For more information about phase-1 studies at the UC Cancer Institute, call 513-584-7698 or 866-724-CURE-2873. To learn more about the Experimental Therapeutics Program, visit cancer.uc.edu. Rixe treats patients at the Barrett Center and University Hospital as part of UC Health's multidisciplinary neuro-oncology team.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2012-02/uoca-df021512.php
luol deng culkin wooly mammoth no child left behind no child left behind neurofibromatosis obama birth control
Wednesday, February 15, 2012
My wife wants Double French Doors and now I need Screens!
58 views
Print??|?Classic Home Improvement Products has the solution for you!
Orange, CA, February 14, 2012 ? My wife wants Double French Doors and now I need Screens!?
Let?s face it Double French Doors are a big improvement that has dressed up the Front and Back Doorways of many homes over the years, but where do you find Screens that will complement the opening and keep out the bugs?
Classic Home Improvement Products has the solution for you! Whether you have a brand new set of Double French Doors, or if they are existing French Doors that have been there for years we can install ourStowAway Retractable Screen Door on your French Double Doors.
The process is simple! Once you decided that a StowAway Invisible Screen is right for you a representative will come to your home to measure your Double Door Way, help you pick a color, your close type and go over your mesh options. The lead time for your StowAway Hiding Screen is approximately 14 business days, and yourRetractable Screen is built 100% in the USA. Once the Screen has been built to fit your opening our Master Installers will come out to install your screen in next to no time.
StowAway Retractable Screen Doors can be installed on either Double Doors that Swing In or Double Doorsthat Swing Out without intruding into the Door Way, and without a center obstruction. StowAway Retractable Screen Doors have many upgrades available which includes the Position Holder which is very popular on Double French Door Retractable Screens. The Position Holder is designed to lock into place using a pin latch, and keeps the Inactive Side of the Retractable Screen extended while allowing your to open and close the Active Side of theScreen.
Want to learn more about StowAway Retractable Screen Doors for your Double French Doors? We are just a phone call away
?
?
Classic Home Improvement Products, Inc.
5538 East La Palma Ave.
Anaheim Hills, Ca 92807
Toll Free 866 217 9749 (Corporate Office)
Website: www.CHIproducts.com
Our Product Line Includes: StowAway Retractable Screen Doors, Panorama Wide Format Power Screens, PanoramaLite Pull Down Screens, Centor Architectural Screens, Manual Drop Screens,Interior Plantation Shutters, Exterior Shutters, Closet Doors, Flower Boxes, Blinds, Shades, Awnings,Interior Doors, Security Roll Shutters & Shower Doors!
SMT
?
Other press releases from Classic Home Improvement Products, Inc.
Source: http://www.seopressreleases.com/wife-double-french-doors-screens/35682
matt barnes jim jones hcm loretta lynn gene kelly zoe saldana andrew bailey
Quickest Ways With Making Money ? Online Jobs ...
pub-5937285654549581
You can always enjoy good sums of money if you know how to hunt for online jobs and make easy money. There are so many opportunities that are within the realm of the internet and if you are only enthusiastic to find them you would not be getting short of cash or feel the crisis in many small ways. Making money online jobs are not really hard to find if you know how to use the internet as the basic tool in accessing these opportunities and you can choose from a wide variety of jobs that are involved in marketing and sales, affiliate marketing, article writing, doing paid surveys, web designing and so on.
To start with, internet marketing is an online job that does not require people to have their degrees. As long as your inclination is in marketing, you have the chance to be successful in marketing online business. You just have to observe, study and learn some pointers in the ways of online marketing. Unlike personal marketing, online marketing needs you to know the basics of the trade such as how people use the internet in buying and selling products, how globalization influence business, and how you can use the web in promoting your products. Remember that the internet is called the World Wide Web and if you will be doing online marketing then you also have to deal with not only groups of people but millions of people all over the world.
pub-5937285654549581Affiliate marketing is also another form of marketing that require crowd sourcing which means you will be rewarded by companies whenever you refer a customer to visit their websites. Although some people see that affiliate marketing possess the same characteristics as with the standard online marketing, affiliate marketing require you to advertise other websites other than products so it is no doubt that it is one of the fastest ways among making money online jobs that can bring you fruitful and easy income.
pub-5937285654549581Earning extra money can also be quick with article marketing especially if you are fond of writing. All you have to do is to look for online companies that offer internet freelance writing jobs and cater for web content articles. The companies will ask written samples from your recent works to know your writing capabilities and then when they accept you as their writer you can rewrite prevailing articles that can be easily found on the web. Some companies also give their writers different websites which the writers need to write good articles to promote the products that are within the websites. The good thing about article writing is that topics can vary in many different fields and you may be required to write only about 300-500 words 10 article compositions a day. The pay in this scheme is greater than doing online paid surveys and data entries.
Other than these, people with different skills can also use their talents to take on making money online jobs as part of their money making prospects. There is the very simple survey completion, assistance with SEOs, to the more complex web designing, remote programming and virtual assistance. Salaries for these jobs vary because of the tasks required so better choose from any of these job selections and pick the one where you can excel best. Start hunting for your own online job now and don?t just waste your time being idle or do work that does not compensate your skills.
About this Author
Ready To Start Your Own Internet Based Business And Make Real Money Online? For A Limited Time Only ? Go To http://www.InternetBasedBusiness.com For Your FREE eBook That Reveals The Secrets To Getting Your Own Profitable Internet Business In 24 Hours Or Less!
This entry was posted in Uncategorized and tagged Making, Money, Online, Quickest. Bookmark the permalink.Source: http://workingonlinejobs.com/?p=5
bears lions heavy d heavy d taser gun patriots vs jets adventureland sean hannity
Subscribe to:
Posts (Atom)